Document Detail


Advanced age is a significant determinant of poor prognosis in patients treated with surgery plus postoperative radiotherapy for endometrial cancer.
MedLine Citation:
PMID:  20666941     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: A review was conducted in which the effect of age on survival was assessed in a population of endometrial cancer patients treated with surgery and adjuvant radiation therapy in our institution.
METHODS: From 1988 to 2008, 111 endometrial cancer patients underwent total abdominal hysterectomy and adjuvant whole pelvic radiation therapy (RT). After surgery, for patients with low or intermediate risk without lymph node metastasis, no postoperative adjuvant therapy was performed. For patients with high risk or positive cytology from the abdominal cavity, postoperative radiation therapy was performed. A total dose of 50-50.4 Gy of RT was delivered sequentially. Forty-four patients (44%) were given chemotherapy consisting of epirubicin/cisplatin/carboplatin or paclitaxel/carboplatin. Univariate and multivariate analyses were performed to identify significant prognostic clinicopathological factors.
RESULTS: With a median follow-up time of 59.2 months, the 5-year overall survival was 74% for those 60 years or older versus 90% for those younger than 60 years (P = 0.044). For disease-free survival, it was 65% for those 60 years or older, versus 85% for those younger than 60 years (P = 0.013). On multivariate analysis, poor disease-free survival was associated with age > or = 60 years (P = 0.035).
CONCLUSIONS: Older patients (age > or = 60 years) with endometrial cancer had significantly lower overall survival and disease-free survival following postoperative RT independent of other prognostic factors and/or treatment technique.
Authors:
Kae Okuma; Hideomi Yamashita; Kei Kawana; Shunsuke Nakagawa; Katsutoshi Oda; Keiichi Nakagawa
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The journal of obstetrics and gynaecology research     Volume:  36     ISSN:  1447-0756     ISO Abbreviation:  J. Obstet. Gynaecol. Res.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-29     Completed Date:  2010-11-04     Revised Date:  2012-01-19    
Medline Journal Info:
Nlm Unique ID:  9612761     Medline TA:  J Obstet Gynaecol Res     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  757-63     Citation Subset:  IM    
Affiliation:
Department of Radiology, University of Tokyo Hospital, Hongo, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Aged
Carcinoma / drug therapy,  radiotherapy*,  surgery*
Chemotherapy, Adjuvant
Cisplatin / therapeutic use
Disease-Free Survival
Endometrial Neoplasms / drug therapy,  radiotherapy*,  surgery*
Female
Humans
Hysterectomy
Kaplan-Meier Estimate
Middle Aged
Multivariate Analysis
Paclitaxel / therapeutic use
Prognosis
Radiotherapy, Adjuvant
Treatment Outcome
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin; 33069-62-4/Paclitaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical diagnosis and treatment of acute fatty liver of pregnancy: a literature review and 11 new c...
Next Document:  Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithel...